SCHEMBL4728352

SCHEMBL4728352

ON=C(Nc1ccc(F)c(Cl)c1)c1ccno1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.49
KMT2A Q03164 8/20 0.49
MAPT P10636 4/20 0.49
HTT P42858 3/20 0.49
ALDH1A1 P00352 3/20 0.49
NPSR1 Q6W5P4 1/20 0.49
LMNA P02545 5/20 0.48
SMN1; SMN2 Q16637 7/20 0.46
SLC2A1 P11166 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
KDM4E B2RXH2 1/20 0.44
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
GAA P10253 1/20 0.42
GFER P55789 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4728350 1.00 MEN1 (0.49) MEN1KMT2AMAPTHTTALDH1A1
SCHEMBL14259998 0.82 MEN1 (0.50) MEN1KMT2AMAPTHTTALDH1A1
SCHEMBL2184140 0.81 MEN1 (0.52) MEN1KMT2AMAPTHTTALDH1A1
SCHEMBL2184135 0.81 MEN1 (0.52) MEN1KMT2AMAPTHTTALDH1A1
SCHEMBL4727448 0.80 GRM4 (0.48) MEN1KMT2AGAAGFER
SCHEMBL4727441 0.80 GRM4 (0.48) MEN1KMT2AGAAGFER
SCHEMBL2183730 0.80 MEN1 (0.71) MEN1KMT2AMAPTHTTALDH1A1
SCHEMBL2183725 0.80 MEN1 (0.71) MEN1KMT2AMAPTHTTALDH1A1
SCHEMBL4726883 0.78 KMT2A (0.59) MEN1KMT2AMAPTHTTALDH1A1
SCHEMBL4726885 0.78 KMT2A (0.59) MEN1KMT2AMAPTHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080146624-A1 AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-06-19 US claimed
WO-2008036652-A2 AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-03-27 WO claimed
US-20080146624-A1 AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-06-19 US disclosed
US-20080146624-A1 AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146624-A1 AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, INMT MEN1 1795/4885KMT2A 636/4885MAPT 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.